Genfit Shares Rise as Iqirvo Royalties Triple

Key Facts

1Genfit shares rose 4% following the announcement that royalties for the drug Iqirvo have tripled.

2The company confirmed that its current cash runway is sufficient to fund operations beyond 2028.

Genfit shares rose 4% following the announcement that royalties for the drug Iqirvo have tripled. Investing.com reported that this significant increase in royalty income has driven the upward movement in the stock price.

The company confirmed that its current cash runway is sufficient to fund operations beyond 2028. This extension of financial stability is supported by the surge in royalty payments, providing a positive outlook for the firm's long-term operational funding.